Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
24 févr. 2022 16h05 HE
|
Relay Therapeutics, Inc.
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
17 févr. 2022 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
02 févr. 2022 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference...
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
04 janv. 2022 07h30 HE
|
Relay Therapeutics, Inc.
Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 and initiates expansion cohorts in patients...
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022...
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
10 déc. 2021 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
10 nov. 2021 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
04 nov. 2021 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
12 oct. 2021 21h58 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Proposed Public Offering of Common Stock
11 oct. 2021 16h15 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...